<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INJECTAFER- ferric carboxymaltose injection, solution </strong><br>American Regent, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use Injectafer safely and effectively. See full prescribing information for Injectafer.</span><br><span class="Bold">INJECTAFER<span class="Sup">®</span> (ferric carboxymaltose injection) <br></span><span class="Bold">For intravenous use<br></span><span class="Bold">Initial U.S. Approval: 2013</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Injectafer is an iron replacement product indicated for the treatment of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> in adult patients: </p>
<ul class="Disk">
<li>who have intolerance to oral iron or have had unsatisfactory response to oral iron; 
</li>
<li>who have non-dialysis dependent <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>. (<a href="#LINK_a2ee7b00-a8dd-4212-8d96-70f1cb1cc2e5">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For patients weighing 50 kg (110 lb) or more:  Give Injectafer in two doses separated by at least 7 days.  Give each dose as 750 mg for a total cumulative dose of 1500 mg of iron per course. </p>
<p class="Highlighta">For patients weighing less than 50 kg (110 lb):  Give Injectafer in two doses separated by at least 7 days and give each dose as 15 mg/kg body weight.   </p>
<p class="Highlighta">Injectafer treatment may be repeated if <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> reoccurs. (<a href="#LINK_d2e08c93-4655-48fa-af9f-8c2aaea33690">2</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">750 mg iron/15 mL single-use vial.  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Injectafer or any of its inactive components.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>:</span>  Observe for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of each administration. (<a href="#LINK_ef0e9286-555b-4454-b600-4311ab695680">5.1</a>)<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:</span>  Monitor patients closely for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> following each Injectafer administration. (<a href="#LINK_7319ebac-8970-4332-8c63-559ef19abb24">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common adverse reactions (≥ 2%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. (<a href="#LINK_0b06ee90-3165-413e-8c52-cc714e7299d3">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact American Regent at 1-800-734-9236 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk"><li>Nursing Mothers: Exercise caution when administered to a nursing woman. (<a href="#LINK_516c0e71-85b1-4296-8939-635cd0b21dfe">8.3</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Laboratory Test Alterations</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adverse Reactions in Clinical Trials</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Trial 1: <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">Iron Deficiency Anemia</span> in Patients Who Are Intolerant to Oral Iron or Have Had Unsatisfactory Response to Oral Iron</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Trial 2: <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">Iron Deficiency Anemia</span> in Patients with Non-Dialysis Dependent <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a2ee7b00-a8dd-4212-8d96-70f1cb1cc2e5"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Injectafer is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> in adult patients:</p>
<ul class="Disk">
<li>who have intolerance to oral iron or have had unsatisfactory response to oral iron;
</li>
<li>who have non-dialysis dependent <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d2e08c93-4655-48fa-af9f-8c2aaea33690"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">For patients weighing 50 kg (110 lb) or more:  Give Injectafer in two doses separated by at least 7 days.  Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.</p>
<p>For patients weighing less than 50 kg (110 lb):  Give Injectafer in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.  </p>
<p>The dosage of Injectafer is expressed in mg of elemental iron. Each mL of Injectafer contains 50 mg of elemental iron.  Injectafer treatment may be repeated if <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> reoccurs.  </p>
<p>Administer Injectafer intravenously, either as an undiluted slow intravenous push or by infusion.  When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute.  When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.</p>
<p>When added to an infusion bag containing 0.9% sodium chloride injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Injectafer solution is physically and chemically stable for 72 hours when stored at room temperature.  To maintain stability, do not dilute to concentrations less than 2 mg iron/mL. </p>
<p>Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration.  The product contains no preservatives. Each vial of Injectafer is intended for single-use only. Any unused drug remaining after injection must be discarded.</p>
<p>Avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of Injectafer since brown discoloration of the <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> site may be long lasting.  Monitor for <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.  If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occurs, discontinue the Injectafer administration at that site.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_6ad8a31d-087e-4393-90ee-45cd58ef8963"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">750 mg iron/15 mL single-use vial</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_f63a23a0-9d64-49b5-af74-09f285aac7ea"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Injectafer or any of its components [see <span class="Italics">Warnings and Precautions (<a href="#LINK_ef0e9286-555b-4454-b600-4311ab695680">5.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_31f22111-d251-4c0c-bc63-16d09e7a22d6"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ef0e9286-555b-4454-b600-4311ab695680"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></h2>
<p class="First"><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, and/or collapse. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</span> [see <span class="Italics">Adverse Reactions (<a href="#LINK_0b06ee90-3165-413e-8c52-cc714e7299d3">6.1</a> and <a href="#LINK_9711fcf5-19ff-4f74-b0a7-7aeafc202924">6.2</a>)</span>]<span class="Italics">.</span>  In clinical trials, serious anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> which included, but not limited to, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> were reported in 1.5% (26/1775) of these subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7319ebac-8970-4332-8c63-559ef19abb24"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></h2>
<p class="First">In clinical studies, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was reported in 3.8% (67/1,775) of subjects in clinical trials 1 and 2. Transient elevations in systolic blood pressure, sometimes occurring with <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> were observed in 6% (106/1,775) of subjects in these two clinical trials. These elevations generally occurred immediately after dosing and resolved within 30 minutes.   Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> following each Injectafer administration [<span class="Italics">see Dosage and Administration (<a href="#LINK_d2e08c93-4655-48fa-af9f-8c2aaea33690">2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9716b38e-b16c-4c37-87e7-67a73cafd16a"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Laboratory Test Alterations</span></h2>
<p class="First">In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_02485448-be34-4444-bc4b-c806aea0df11"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_ef0e9286-555b-4454-b600-4311ab695680">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_7319ebac-8970-4332-8c63-559ef19abb24">5.2</a>)]</span>
</li>
<li>Laboratory Test Alterations<span class="Italics"> [see Warnings and Precautions (<a href="#LINK_9716b38e-b16c-4c37-87e7-67a73cafd16a">5.3</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0b06ee90-3165-413e-8c52-cc714e7299d3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adverse Reactions in Clinical Trials</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.</p>
<p>In two randomized clinical studies [Studies 1 and 2, <span class="Italics">See Clinical Studies (<a href="#LINK_7c3d4a93-c62b-4c8b-8144-3ee3a3dbed84">14</a>)</span>], a total of 1,775 patients were exposed to Injectafer 15 mg/kg body weight up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1500 mg of iron.</p>
<p>Adverse reactions reported by ≥ 1% of treated patients are shown in the following table.   </p>
<p><span class="Bold">Table 1.   Adverse reactions reported </span><span class="Bold">in ≥ 1% of Study Patients in Clinical Trials</span><span class="Bold"> 1 and 2</span></p>
<table>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes oral iron and all formulations of IV iron other than Injectafer</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Injectafer</span></p>
<p><span class="Bold"><br>(N=1775)<br></span><span class="Bold">%</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Pooled Comparators<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> <br><br></span><span class="Bold">(N=1783)<br></span><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Oral<br></span><span class="Bold">iron<br><br></span><span class="Bold">(N=253)<br></span><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>/<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flush</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">Blood Phosphorus</span> Decrease</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Injection Site Discoloration</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine Aminotransferase</span> Increase</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.2</p></td>
</tr>
</tbody>
</table>
<p>Other adverse reactions reported by ≥ 0.5% of treated patients include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, gamma glutamyl transferase increased, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>/irritation, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>. Transient decreases in laboratory <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">blood phosphorus</span> levels (&lt; 2 mg/dL) have been observed in 27% (440/1638) patients in clinical trials. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9711fcf5-19ff-4f74-b0a7-7aeafc202924"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First">Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports with Injectafer:  <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pruritis, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. One case of hypophosphatemic <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> was reported in a subject who received 500 mg of Injectafer every 2 weeks for a total of 16 weeks.  Partial recovery followed discontinuation of Injectafer. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_e46a4f19-823d-436e-8ea7-ccc256d8218c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Formal drug interaction studies have not been performed with Injectafer. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_2932b71d-9397-45e6-a739-295e2018f749"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_41009d9f-4080-4ce7-ac35-cf2e923e1550"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C </p>
<p><span class="Italics"><span class="Underline">Risk Summary</span></span></p>
<p>Adequate and well controlled studies in pregnant women have not been conducted.    However, animal reproduction studies have been conducted with ferric carboxymaltose. In these studies, administration of ferric carboxymaltose to rabbits during the period of organogenesis caused <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> and increased implantation loss at maternally toxic doses of approximately 12% to 23% of the human weekly dose of 750 mg (based on body surface area).  The incidence of major malformations in human pregnancies has not been established for Injectafer. However, all pregnancies, regardless of exposure to any drug, has a background rate of 2 to 4% for major malformations, and 15 to 20% for pregnancy loss. Injectafer should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  </p>
<p><span class="Italics"><span class="Underline">Animal Data</span></span></p>
<p>Administration of ferric carboxymaltose to rats as a one-hour intravenous infusion up to 30 mg/kg/day iron on gestation days 6 to 17 did not result in adverse embryofetal findings.  This daily dose in rats is approximately 40% of the human weekly dose of 750 mg based on body surface area.  In rabbits, ferric carboxymaltose was administered as a one-hour infusion on gestation days 6 to 19 at iron doses of 4.5, 9, 13.5, and 18 mg/kg/day.  Malformations were seen starting at the daily dose of 9 mg/kg (23% of the human weekly dose of 750 mg).  <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Spontaneous abortions</span> occurred starting at the daily iron dose of 4.5 mg/kg (12% of the human weekly dose based on body surface area).  Pre-implantation loss was at the highest dose.  Adverse embryofetal effects were observed in the presence of maternal toxicity.</p>
<p>A pre- and post-natal development study was conducted in rats at intravenous doses up to 18 mg/kg/day of iron (approximately 23% of the weekly human dose of 750 mg on a body surface area basis).  There were no adverse effects on survival of offspring, their behavior, sexual maturation or reproductive parameters. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_516c0e71-85b1-4296-8939-635cd0b21dfe"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">A study to determine iron concentrations in breast milk after administration of Injectafer (n=11) or oral ferrous sulfate (n=14) was conducted in 25 lactating women with postpartum <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>.  Mean breast milk iron levels were higher in lactating women receiving Injectafer than in lactating women receiving oral ferrous sulfate.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_5dc08224-9c97-491d-af5d-15225afe4f21"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness have not been established in pediatric patients. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_a1a80558-63c9-4fe8-b686-9255164bae93"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 1775 subjects in clinical studies of Injectafer, 50% were 65 years and over, while 25% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_b1bca010-ef6f-46cd-a427-67b8168fbab4"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Excessive dosages of Injectafer may lead to accumulation of iron in storage sites potentially leading to <span class="product-label-link" type="condition" conceptid="4305596" conceptname="Hemosiderosis">hemosiderosis</span>. A patient who received Injectafer 18,000 mg over 6 months developed <span class="product-label-link" type="condition" conceptid="4305596" conceptname="Hemosiderosis">hemosiderosis</span> with multiple <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, walking <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Hypophosphatemic <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> was reported in a patient who received Injectafer 4000 mg over 4 months. Partial recovery followed discontinuation of Injectafer. [<span class="Italics">see Post-marketing Experience (<a href="#LINK_9711fcf5-19ff-4f74-b0a7-7aeafc202924">6.2</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_58c588e8-25a6-43ec-b51a-6df7986a7142"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Ferric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III) hydroxide 4(R)-(poly-(1→4)-<span class="Italics">O</span>-α-D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate. It has a relative molecular weight of approximately 150,000 Da corresponding to the following empirical formula:</p>
<p>[FeO<span class="Sub">x</span>(OH)<span class="Sub">y</span>(H<span class="Sub">2</span>O)<span class="Sub">z</span>]<span class="Sub">n</span> [{(C<span class="Sub">6</span>H<span class="Sub">10</span>O<span class="Sub">5</span>)<span class="Sub">m</span> (C<span class="Sub">6</span>H<span class="Sub">12</span>O<span class="Sub">7</span>)}<span class="Italics"><span class="Sub">l</span></span>]<span class="Sub">k</span>,  </p>
<p>where n ≈ 10<span class="Sup">3</span>, m ≈ 8, <span class="Italics">l ≈ </span>11, and <span class="Italics">k</span> ≈ 4<br>(<span class="Italics">l </span>represents the mean branching degree of the ligand). </p>
<p>The chemical structure is presented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de&amp;name=injectafer-ferric-carboxymaltose-injection-1.jpg"></div>
<p>Injectafer (ferric carboxymaltose injection) is a dark brown, sterile, aqueous, isotonic colloidal solution for intravenous injection. Each mL contains 50 mg iron as ferric carboxymaltose in water for injection.  Injectafer is available in 15 mL single-use vials.  Sodium hydroxide and/or hydrochloric acid may have been added to adjust the pH to 5.0-7.0. </p>
<p>Vial closure is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_7ab5f39b-64ff-4c85-8a2f-cb1d8850f95c"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_b64626e2-6ff9-4235-8c84-b8af300fe4ab"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_cb1ec734-33bc-444a-9e3e-46eb46758d5c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Using positron emission tomography (PET) it was demonstrated that red cell uptake of <span class="Sup">59</span>Fe and <span class="Sup">52</span>Fe from Injectafer ranged from 61% to 99%. In patients with <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>, red cell uptake of radio-labeled iron ranged from 91% to 99% at 24 days after Injectafer dose. In patients with renal <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> red cell uptake of radio-labeled iron ranged from 61% to 84% after 24 days Injectafer dose.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_60dba568-f259-409d-97a4-c5e01f90606e"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">After administration of a single dose of Injectafer of 100 to 1000 mg of iron in iron deficient patients, maximum iron levels of 37 µg/mL to 333 µg/mL were obtained respectively after 15 minutes to 1.21 hours post dose. The volume of distribution was estimated to be 3 L.</p>
<p>The iron injected or infused was rapidly cleared from the plasma, the terminal half-life ranged from 7 to 12 hours. Renal elimination of iron was negligible.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_a6301c8a-d26a-4c02-ad4b-37843aff5692"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_bc836e08-420c-4463-b5f8-fd0660663788"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been performed with ferric carboxymaltose.</p>
<p>Ferric carboxymaltose was not genotoxic in the following genetic toxicology studies: <span class="Italics">in vitro</span> microbial mutagenesis (Ames) assay, <span class="Italics">in vitro</span> chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="Italics">in vitro</span> mammalian cell mutation assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> L5178Y/TK+/- cells, <span class="Italics">in vivo</span> mouse micronucleus test at single intravenous doses up to 500 mg/kg.  </p>
<p>In a combined male and female fertility study, ferric carboxymaltose was administered intravenously over one hour to male and female rats at iron doses of up to 30 mg/kg.  Animals were dosed 3 times per week (on Days 0, 3, and 7).  There was no effect on mating function, fertility or early embryonic development. The dose of 30 mg/kg in animals is approximately 40% of the human dose of 750 mg based on body surface area. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_7c3d4a93-c62b-4c8b-8144-3ee3a3dbed84"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of Injectafer for treatment of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> were evaluated in two randomized, open-label, controlled clinical trials (Trial 1 and Trial 2). In these two trials, Injectafer was administered at a dose of 15 mg/kg body weight up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1500 mg of iron. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46c74733-5dfe-49ae-99d9-f20891db67d4"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Trial 1: <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">Iron Deficiency Anemia</span> in Patients Who Are Intolerant to Oral Iron or Have Had Unsatisfactory Response to Oral Iron</h2>
<p class="First">Trial 1 was a randomized, open-label, controlled clinical study in patients with <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> who had an unsatisfactory response to oral iron (Cohort 1) or who were intolerant to oral iron (Cohort 2) during the 14 day oral iron run-in period. Inclusion criteria prior to randomization included hemoglobin (Hb) &lt;12 g/dL, ferritin ≤ 100 ng/mL or ferritin ≤ 300 ng/mL when <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> (TSAT) ≤ 30%. Cohort 1 subjects were randomized to Injectafer or oral iron for 14 more days.  Cohort 2 subjects were randomized to Injectafer or another IV iron per standard of care [90% of subjects received iron sucrose]. The mean age of study patients was 43 years (range, 18 to 94); 94% were female; 42% were Caucasian, 32% were African American, 24% were Hispanic, and 2% were other races. The primary etiologies of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> were heavy <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> (47%) and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> (17%). </p>
<p>Table 2 shows the baseline and the change in hemoglobin from baseline to highest value between baseline and Day 35 or time of intervention.  </p>
<p><span class="Bold">Table 2. Mean Change in Hemoglobin From Baseline to the Highest Value Between Day 35 or Time of Intervention (Modified Intent‑to‑Treat Population)</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">
<p class="First"><span class="Bold">Hemoglobin (g/dL)</span></p>
<p><span class="Bold">Mean (SD)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Cohort 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Cohort 2</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Injectafer<br></span><span class="Bold">(N=244)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Oral Iron<br>(N=251)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Injectafer<br></span><span class="Bold">(N=245)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">IV SC<span class="Sup">a</span><br>(N=237)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Baseline           </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10.6 (1.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10.6 (1.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9.1 (1.6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9.0 (1.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Highest Value</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12.2 (1.1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11.4 (1.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12.0 (1.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11.2 (1.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Change (from baseline to highest value)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.6 (1.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.8 (0.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.9 (1.6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.2 (1.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">p-value</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">0.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">0.001</p></td>
</tr>
</tbody>
</table>
<p>SD=standard deviation; <span class="Sup">a</span>: Intravenous iron per standard of care</p>
<p>Increases from baseline in mean ferritin (264.2 ± 224.2 ng/mL in Cohort 1 and 218.2 ± 211.4 ng/mL in Cohort 2), and <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> (13 ± 16% in Cohort 1 and 20 ± 15% in Cohort 2) were observed at Day 35 in Injectafer-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d280d597-f14c-4d34-968d-6b7741b3f893"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Trial 2: <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">Iron Deficiency Anemia</span> in Patients with Non-Dialysis Dependent <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic Kidney Disease</span></h2>
<p class="First">Trial 2 was a randomized, open-label, controlled clinical study in patients with non-dialysis dependent <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>. Inclusion criteria included hemoglobin (Hb) ≤ 11.5 g/dL, ferritin ≤ 100 ng/mL or ferritin ≤ 300 ng/mL when <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> (TSAT) ≤ 30%.  Study patients were randomized to either Injectafer or Venofer. The mean age of study patients was 67 years (range, 19 to 96); 64% were female; 54% were Caucasian, 26% were African American, 18% Hispanics, and 2% were other races. </p>
<p>Table 3 shows the baseline and the change in hemoglobin from baseline to highest value between baseline and Day 56 or time of intervention.  </p>
<p><span class="Bold">Table 3. Mean Change in Hemoglobin From Baseline to the Highest Value Between Baseline  and Day 56 or Time of Intervention (Modified Intent‑to‑Treat Population)</span></p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Hemoglobin (g/dL)<br></span><span class="Bold">Mean (SD)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Injectafer<br></span><span class="Bold">(N=1249)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Venofer<br>(N=1244)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Baseline</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10.3 (0.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10.3 (0.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Highest Value </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11.4 (1.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11.3 (1.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Change (from baseline to highest value)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.1 (1.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.9 (0.92)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Treatment Difference (95% CI)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">0.21 (0.13, 0.28)</p></td>
</tr>
</tbody>
</table>
<p>Increases from baseline in mean ferritin (734.7 ± 337.8 ng/mL), and <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> (30 ± 17%) were observed at Day 56 in Injectafer-treated patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_aab244c2-373c-43f5-a52d-78fef2838eef"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC 0517-0650-01           750 mg iron/15 mL Single-Use Vial        Individually boxed<br>NDC 0517-0650-02           750 mg iron/15 mL Single-Use Vial        Packages of 2</p>
<p>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See the USP controlled room temperature].  Do not freeze. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_53535bce-a3d4-49ab-8402-e35fc1c0344e"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul class="Disk">
<li>Question patients regarding any prior history of reactions to parenteral iron products.</li>
<li>Advise patients of the risks associated with Injectafer. 
</li>
<li>Advise patients to report any signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> that may develop during and following Injectafer administration, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and breathing problems [<span class="Italics">see Warnings and Precautions (<a href="#LINK_31f22111-d251-4c0c-bc63-16d09e7a22d6">5</a>)</span>].</li>
</ul>
<p class="First">Injectafer is manufactured under license from Vifor (International) Inc, Switzerland.</p>
<p><span class="Bold">AMERICAN<br></span><span class="Bold">REGENT, INC.<br></span><span class="Bold">SHIRLEY, NY  11967</span></p>
<p>IN0650<br>RQ1052</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_c93f71d9-5676-4ae9-a9b2-a1a45243349c"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">INJECTAFER (ferric carboxymaltose injection)</span></p>
<p>Please read this information carefully before taking this medication. This summary does not tell you everything about INJECTAFER. Speak with your doctor or healthcare professional if there is something you do not understand or if you would like to learn more about INJECTAFER. Your doctor or healthcare professional is your best source of information about this medicine.</p>
<p><span class="Bold"><span class="Underline">What is INJECTAFER</span></span><span class="Bold"><span class="Underline">?</span></span></p>
<p>Iron is a mineral that the body needs to produce red blood cells. When the body does not get enough iron, it cannot produce the number of normal red blood cells needed to keep you in good health. This condition is called <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> (iron shortage) or <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>. </p>
<p>INJECTAFER is used to treat <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>. <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">Iron deficiency anemia</span> may be caused by several medical conditions including heavy menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, pregnancy, childbirth, <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, other <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> diseases, bariatric surgery, or <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span><span class="Bold">. </span></p>
<p><span class="Bold"><span class="Underline">General information about using INJECTAFER safely and effectively</span></span></p>
<p>Injectable iron is administered only by or under the supervision of your health care professional.</p>
<p>Serious or life threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported with intravenous iron products. Tell your health care professional if you have ever had any unusual or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to any IV iron.</p>
<p>Patients should report to their healthcare professional any signs and symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to INJECTAFER, in particular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. </p>
<p>Iron is not easily eliminated from the body, and its build up may be lead to a condition called <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> which may be harmful.  Certain medical conditions such as liver disease may also make you more likely to develop <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span>. Ask your doctor or healthcare professional.</p>
<p><span class="Bold"><span class="Underline">Who should not take INJECTAFER?</span></span></p>
<p>You should not be given INJECTAFERif you have <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> that is not caused by <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>, or if you have <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span>.</p>
<p>If you are pregnant or plan to become pregnant please notify your doctor or healthcare professional. They will decide whether it is safe for you to receive INJECTAFER. </p>
<p><span class="Bold"><span class="Underline">How should I take INJECTAFER</span></span><span class="Bold"><span class="Underline">?</span></span></p>
<p>INJECTAFER is administered intravenously (into your vein) by your doctor or health care professional in two doses. </p>
<p><span class="Bold"><span class="Underline">What should I avoid while taking INJECTAFER?</span></span></p>
<p>You should not take iron supplements by mouth if you are receiving iron injections. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.</p>
<p><span class="Bold"><span class="Underline">What are the possible side effects of INJECTAFER?</span></span></p>
<p>The side effects of INJECTAFERare infrequent, usually mild and generally do not cause patients to stop treatment. The most common side effects are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> at the injection site), asymptomatic reductions in <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">blood phosphorus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and increased <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>. Potentially long lasting brown staining of skin near injection site may occur.  </p>
<p>These are not all the possible side effects of INJECTAFER. For more information ask your doctor or healthcare professional.   </p>
<p>Talk to your doctor if you think you have side effects from taking INJECTAFER.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_a72857f5-3e8e-4de1-9061-bf33e044e045"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15 ML CONTAINER</h1>
<p class="First">NDC 0517-0650-01<br>Injectafer®<br>(ferric carboxymaltose injection)<br><span class="Bold">750 mg/15 mL<br></span>(50 mg/mL)<br><span class="Bold">FOR INTRAVENOUS USE ONLY<br></span>Single Dose Vial.<br>Discard Unused Portion.<br>Rx Only<br>AMERICAN<br>REGENT, INC.<br>SHIRLEY, NY  11967</p>
<div class="Figure"><img alt="Inejctafer 15 mL Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de&amp;name=injectafer-ferric-carboxymaltose-injection-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_2fb434d3-489c-4587-808b-1eafeb32d58d"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15 ML CARTON</h1>
<p class="First">NDC 0517-0650-01<br>Injectafer®<br>(ferric carboxymaltose injection)<br><span class="Bold">750 mg/15 mL<br></span>(50 mg/mL)<br><span class="Bold">FOR INTRAVENOUS USE ONLY<br></span>Single Dose Vial.<br>Discard Unused Portion.<br>Rx Only<br>AMERICAN<br>REGENT, INC.<br>SHIRLEY, NY  11967</p>
<div class="Figure"><img alt="Injectafer 15 mL Carton Labeling (single pack)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de&amp;name=injectafer-ferric-carboxymaltose-injection-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INJECTAFER 		
					</strong><br><span class="contentTableReg">ferric carboxymaltose injection injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-0650</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FERRIC CARBOXYMALTOSE</strong> (FERRIC CATION) </td>
<td class="formItem">FERRIC CATION</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-0650-01</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203565</td>
<td class="formItem">08/12/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PharmaForce, Inc.</td>
<td class="formItem"></td>
<td class="formItem">113894740</td>
<td class="formItem">ANALYSIS(0517-0650)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PharmaForce, Inc.</td>
<td class="formItem"></td>
<td class="formItem">606821721</td>
<td class="formItem">MANUFACTURE(0517-0650)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Vifor (International) Inc.</td>
<td class="formItem"></td>
<td class="formItem">482603065</td>
<td class="formItem">API MANUFACTURE(0517-0650)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>08a40e1f-f305-49fb-a702-43438323701a</div>
<div>Set id: 517b4a19-45b3-4286-9f6a-ced4e10447de</div>
<div>Version: 3</div>
<div>Effective Time: 20130729</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
